Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Skjelbo

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
British Journal of Clinical Pharmacology|September 1, 1992
Inhibitors of imipramine metabolism by human liver microsomesE Skjelbo, K Brøsen
British Journal of Clinical Pharmacology|August 1, 1993
Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in DenmarkK Brøsen, E Skjelbo, H Flachs
British Journal of Clinical Pharmacology|March 1, 1993
The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population studyE Skjelbo, L F Gram, K Brøsen
Clinical Pharmacology and Therapeutics|January 1, 1991
The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramineE Skjelbo, K Brøsen, J Hallas, et al.
Biochemical Pharmacology|March 24, 1993
Fluvoxamine is a potent inhibitor of cytochrome P4501A2K Brøsen, E Skjelbo, B B Rasmussen, et al.
British Journal of Clinical Pharmacology|October 6, 1999
Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian populationL Bathum, E Skjelbo, T K Mutabingwa, et al.
Clinical Pharmacology and Therapeutics|March 1, 1996
Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in TanzaniansE Skjelbo, T K Mutabingwa, I b Bygbjerg, et al.
British Journal of Clinical Pharmacology|June 1, 1991
The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel studyS A Ward, N A Helsby, E Skjelbo, et al.
Clinical Pharmacology and Therapeutics|March 1, 1992
The relationship between paroxetine and the sparteine oxidation polymorphismS H Sindrup, K Brøsen, L F Gram, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
British Journal of Clinical Pharmacology|September 1, 1992
Inhibitors of imipramine metabolism by human liver microsomesE Skjelbo, K Brøsen
British Journal of Clinical Pharmacology|August 1, 1993
Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in DenmarkK Brøsen, E Skjelbo, H Flachs
British Journal of Clinical Pharmacology|March 1, 1993
The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population studyE Skjelbo, L F Gram, K Brøsen
Clinical Pharmacology and Therapeutics|January 1, 1991
The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramineE Skjelbo, K Brøsen, J Hallas, et al.
Biochemical Pharmacology|March 24, 1993
Fluvoxamine is a potent inhibitor of cytochrome P4501A2K Brøsen, E Skjelbo, B B Rasmussen, et al.
British Journal of Clinical Pharmacology|October 6, 1999
Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian populationL Bathum, E Skjelbo, T K Mutabingwa, et al.
Clinical Pharmacology and Therapeutics|March 1, 1996
Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in TanzaniansE Skjelbo, T K Mutabingwa, I b Bygbjerg, et al.
British Journal of Clinical Pharmacology|June 1, 1991
The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel studyS A Ward, N A Helsby, E Skjelbo, et al.
Clinical Pharmacology and Therapeutics|March 1, 1992
The relationship between paroxetine and the sparteine oxidation polymorphismS H Sindrup, K Brøsen, L F Gram, et al.
Pageof 1